Educational/professional background
I specialized in sociocultural anthropology for my undergraduate degree and went on to complete my MPH focusing on the social determinants of health and global health policy. I previously worked in global health diplomacy for the Federal Government of Canada where I supported Canada鈥檚 relationship with international/ multilateral organizations working on public health and developed Canada鈥檚 positions on public health issues across the United Nations system. I worked closely with the Pan American Health Organization (PAHO), International Agency for Research on Cancer (IARC) and, the World Health Organization Framework Convention on Tobacco Control (FCTC) secretariat. In addition, I also supported Canada's national response to the COVID-19 pandemic.
What I enjoyed most about studying my programme/at LSHTM
I thoroughly enjoyed my time in London! If you're interested in food, culture, history, the city has just about anything and my top tip to take advantage of such a global city! In your cohorts you will most likely study with students from all over the world, from all walks of life, and having had different experiences. Take advantage of this and learn from each other, support one another, and hopefully be able to make some life-long friendships!
What I have been doing since graduating
Since graduating from MSc Epidemiology at LSHTM in 2023, I transitioned to a career in the pharmaceutical industry working in oncology research. Thanks largely to the experience gained during my time at LSHTM, and especially my thesis project, I've gained a newfound passion for the field of real-world evidence research. After graduation, I initially joined Novartis as a real-world evidence research analyst designing, analyzing, and managing observational studies in hematology (chronic-myeloid leukemia). In January 2024, I joined AstraZeneca as a real-world evidence study lead where I have been leading the planning and execution of secondary studies in the GI therapeutic area, specifically in intermediate hepatocellular carcinoma.